FR22C1033I1 - Use of dihydroimidazolones for the treatment of dogs - Google Patents

Use of dihydroimidazolones for the treatment of dogs

Info

Publication number
FR22C1033I1
FR22C1033I1 FR22C1033C FR22C1033C FR22C1033I1 FR 22C1033 I1 FR22C1033 I1 FR 22C1033I1 FR 22C1033 C FR22C1033 C FR 22C1033C FR 22C1033 C FR22C1033 C FR 22C1033C FR 22C1033 I1 FR22C1033 I1 FR 22C1033I1
Authority
FR
France
Prior art keywords
dihydroimidazolones
dogs
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1033C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of FR22C1033I1 publication Critical patent/FR22C1033I1/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1033C 2002-10-10 2022-06-30 Use of dihydroimidazolones for the treatment of dogs Active FR22C1033I1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
EP08167818A EP2036563A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of behavioural abnormalities in dogs
PCT/EP2003/011212 WO2004032938A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs
EP03757945A EP1553952B1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number Publication Date
FR22C1033I1 true FR22C1033I1 (en) 2022-09-09

Family

ID=32094042

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (en) 2002-10-10 2013-07-24 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY
FR22C1033C Active FR22C1033I1 (en) 2002-10-10 2022-06-30 Use of dihydroimidazolones for the treatment of dogs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (en) 2002-10-10 2013-07-24 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY

Country Status (28)

Country Link
US (5) US20050070537A1 (en)
EP (3) EP2036563A1 (en)
JP (4) JP4694202B2 (en)
KR (2) KR101110587B1 (en)
CN (2) CN1726040B (en)
AR (1) AR041573A1 (en)
AT (1) ATE418337T1 (en)
AU (2) AU2003273978B2 (en)
BE (1) BE2013C046I2 (en)
BR (1) BR0315225A (en)
CA (2) CA2727722C (en)
CY (3) CY1109961T1 (en)
DE (1) DE60325496D1 (en)
DK (2) DK2845594T3 (en)
ES (2) ES2316808T3 (en)
FR (2) FR13C0044I2 (en)
HK (1) HK1085920A1 (en)
HR (3) HRP20090667B1 (en)
HU (2) HUS1300035I1 (en)
LU (1) LU92238I2 (en)
MX (1) MXPA05003663A (en)
NZ (1) NZ539864A (en)
PL (2) PL238776B1 (en)
PT (2) PT1553952E (en)
SI (2) SI1553952T1 (en)
TW (2) TWI324067B (en)
WO (1) WO2004032938A1 (en)
ZA (1) ZA200502245B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
UA87982C2 (en) * 2003-07-11 2009-09-10 Берингер Ингельхайм Ветмедика Гмбх Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
RU2014109079A (en) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх PHARMACEUTICAL COMPOSITION WITH MASKED TASTE
JP6193613B2 (en) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 Epilepsy seizure monitoring system and method
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
WO2015182724A1 (en) 2014-05-28 2015-12-03 トーアエイヨー株式会社 Substituted tropane derivatives
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (en) * 1995-09-05 1997-03-06 Dresden Arzneimittel Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation
DE19721580A1 (en) * 1997-05-23 1998-11-26 Dresden Arzneimittel Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension
WO1999000346A1 (en) 1997-06-26 1999-01-07 Board Of Regents, The University Of Texas System Synthesis of dihydrohonokiol compositions
JP4669095B2 (en) * 1999-07-19 2011-04-13 太陽化学株式会社 Composition for suppressing behavioral problems in pets
JP3866715B2 (en) 2002-03-07 2007-01-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 3-[(2-{[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carbonyl) -pyridin-2-yl-amino] -Oral application dosage form of ethyl propionate and its salts
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (en) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
RU2014109079A (en) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх PHARMACEUTICAL COMPOSITION WITH MASKED TASTE
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
HK1085920A1 (en) 2006-09-08
JP2011068685A (en) 2011-04-07
US20050070537A1 (en) 2005-03-31
PL374603A1 (en) 2005-10-31
CY2013031I1 (en) 2015-11-04
US20150072983A1 (en) 2015-03-12
US20130065898A1 (en) 2013-03-14
AU2009225322A1 (en) 2009-11-05
AU2003273978A1 (en) 2004-05-04
EP2845594B1 (en) 2022-02-23
BE2013C046I2 (en) 2022-08-09
TWI424849B (en) 2014-02-01
LU92238I2 (en) 2013-09-03
ZA200502245B (en) 2005-11-30
CY1109961T1 (en) 2014-09-10
US8962617B2 (en) 2015-02-24
HRP20200207A2 (en) 2020-07-24
BR0315225A (en) 2005-08-23
WO2004032938A1 (en) 2004-04-22
US8859540B2 (en) 2014-10-14
JP2014080449A (en) 2014-05-08
JP2016104817A (en) 2016-06-09
DE60325496D1 (en) 2009-02-05
CA2501772C (en) 2011-08-23
US9469611B2 (en) 2016-10-18
ES2316808T3 (en) 2009-04-16
HRP20050322A2 (en) 2006-05-31
TW200503726A (en) 2005-02-01
EP2845594A1 (en) 2015-03-11
FR13C0044I2 (en) 2014-03-07
EP1553952A1 (en) 2005-07-20
KR101110587B1 (en) 2012-02-15
JP4694202B2 (en) 2011-06-08
TWI324067B (en) 2010-05-01
CY1125103T1 (en) 2023-01-05
HUS1300035I1 (en) 2017-10-30
SI1553952T1 (en) 2009-04-30
US20080027057A1 (en) 2008-01-31
AR041573A1 (en) 2005-05-18
CA2727722A1 (en) 2004-04-22
PT2845594T (en) 2022-03-09
PL214702B1 (en) 2013-09-30
MXPA05003663A (en) 2005-06-08
HRP20090667A2 (en) 2010-07-31
KR20050056237A (en) 2005-06-14
CY2013031I2 (en) 2015-11-04
TW201010706A (en) 2010-03-16
KR20110063843A (en) 2011-06-14
EP2036563A1 (en) 2009-03-18
HRP20050322B1 (en) 2013-12-06
PL397320A1 (en) 2012-02-13
EP1553952B1 (en) 2008-12-24
ES2908453T3 (en) 2022-04-29
HRP20090667B1 (en) 2021-06-11
DK1553952T3 (en) 2009-04-20
JP2006503873A (en) 2006-02-02
US20160367562A1 (en) 2016-12-22
CN1726040A (en) 2006-01-25
DK2845594T3 (en) 2022-03-07
NZ539864A (en) 2007-11-30
LU92238I9 (en) 2019-01-09
PT1553952E (en) 2009-02-10
CN101890019A (en) 2010-11-24
PL238776B1 (en) 2021-10-04
FR13C0044I1 (en) 2013-08-30
HUS2200036I1 (en) 2022-08-28
JP6249812B2 (en) 2017-12-20
ATE418337T1 (en) 2009-01-15
CA2501772A1 (en) 2004-04-22
CA2727722C (en) 2013-05-28
AU2003273978B2 (en) 2009-07-23
CN1726040B (en) 2010-05-12
SI2845594T1 (en) 2022-04-29

Similar Documents

Publication Publication Date Title
FR22C1033I1 (en) Use of dihydroimidazolones for the treatment of dogs
MA27395A1 (en) USE OF PREBIOTICS FOR THE TREATMENT AND PREVENTION OF HYPER-GLYCEMIC SYNDROMES
NO20021526L (en) Sewage treatment device
DE60204951D1 (en) CCR5 ANTAGONISTS USE FOR THE TREATMENT OF AIDS
FR2860154B1 (en) COMPOSITION FOR THE TREATMENT OF MALE BREATH
SE0301854L (en) Anti-corrosion treatment
FR2800614B1 (en) COMPOSITION FOR THE TREATMENT OF RESPIRATORY INFECTIONS
FR2868307B1 (en) USE OF BETA-ENDORPHINE FOR THE TREATMENT OF WRINKLES
FR2868312B1 (en) PATCH FOR THE TREATMENT OF LIP
FR2834887B1 (en) USE OF ARTEMIA EXTRACT FOR THE TREATMENT OF OLD SKIN
FR2887456B1 (en) "COMPOSITION FOR THE TREATMENT OF THE SUMMER DERMITE"
DE60133596D1 (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
FR2849599B1 (en) USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
FR2843015B1 (en) IMPLANT FOR THE TREATMENT OF PRESBYOPIA
FR2825893B3 (en) TREATMENT TUNNEL
IT1316554B1 (en) DEVICE FOR THE TREATMENT OF WET WASTE.
FR2839851B1 (en) DEVICE FOR TREATING TREES
FR2855400B1 (en) RECTAL DEVICE, IN PARTICULAR FOR THE TREATMENT OF HEMORRHOIDS
NO20033160D0 (en) Device for the treatment of gravans
FR2820025B1 (en) DEVICE FOR THE TREATMENT OF PRESBYTIA
MA26147A1 (en) EQUIPMENT FOR METAL FINISHING TREATMENT.
FR2879450B1 (en) ANTAGONISTS OF PERIPHERAL RECEPTORS OF BENZODIAZEPINES FOR THE TREATMENT OF DRY SKINS
FR2869603B1 (en) EFFLUENT TREATMENT UNIT
FR2850568B1 (en) USE OF CONDUCTIVE POLYTHIOPHENES FOR THE TREATMENT OF HUMAN KERATINIC MATERIALS
FR2908652B1 (en) USE OF ETHOXUQUINE FOR THE TREATMENT OF CANITIA